Benzinga | Jun 4, 2021 09:24AM EDT

Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC HPN424 at the 2021 ASCO Annual Meeting

* The ongoing dose escalation Phase 1/2a trial has enrolled 89 patients with progressive, metastatic castration-resistant prostate cancer in 13 cohorts.

* Safety data continues to show that HPN424 is generally well tolerated, and cytokine-related adverse events have been transient and manageable.

* Signals of clinical activity include patients with reductions in serum prostate specific antigen (PSA), a confirmed partial response, and patients remaining on study for more than 24 weeks.

* Management to host webcast and conference call to review and update the HPN424 data presented at ASCO and provide a pipeline update today at 4 p.m. ET /1 p.m. PT